Breast Cancer | Unmet Need | US/EU: Advanced/Metastatic Triple-Negative Breast Cancer | 2017
There are limited treatment options for patients with advanced/metastatic, triple-negative breast cancer because commonly used treatments in other breast cancer segments (i.e., hormonal therapies and HER2-targeted therapies) are ineffective in this disease subset. Hence, a high unmet need exists for efficacious targeted therapies for this patient population. Several novel therapies are in development for advanced/metastatic, triple-negative breast cancer; however, historically, it has been difficult for agents to improve outcomes for this hard-to-treat population. Our content examines key drivers of prescribing in this indication and analyses of significant commercial opportunities.
Related Market Assessment Reports
Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…
Report
Diabetic Macular Edema / Diabetic Retinopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Macular Edema (US)
Diabetic macular edema (DME) is a serious complication of diabetic retinopathy caused by persistently elevated blood glucose levels. Without timely treatment, DME can progress to significant vision…
Report
Multiple System Atrophy – Unmet Need – Multiple System Atrophy (US/EU) – Unmet Need – Multiple System Atrophy (US/EU)
Multiple system atrophy (MSA) is a rare, rapidly progressing neurodegenerative synucleinopathy that disrupts movement, balance, and autonomic function. Current management comprises only symptomatic…
